Investigational New Drugs
Springer · United States
✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.
See the official Impact Factor & quartile on the journal’s page ↗The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q2. Source: Clarivate Journal Citation Reports.
Aims & Scope
Investigational New Drugs is a forum for rapid dissemination of information on new anticancer agents. The journal publishes original articles dealing with anticancer drug development. It provides the fastest possible publication of new discoveries for scientists developing anticancer agents. The journal also publishes proceedings of special workshops and symposia on anticancer drug development. It is open to publishing clinical trials with negative results if they contribute to the understanding of investigational agents.
General Information
Submission Info
Ethics & Quality
Think.Check.Submit Compliance
A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.
Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.
Publication & Citation Trend
Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.
SJR Quartile by Discipline
Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.
Subject Classification
Web of Science Categories
Scopus Categories
Research Topics (OpenAlex)
Frequently asked questions about Investigational New Drugs
Is Investigational New Drugs a predatory journal?
PubScope has no integrity flags on record for Investigational New Drugs: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.
What is the impact factor of Investigational New Drugs?
Investigational New Drugs is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 3.21.
Is Investigational New Drugs indexed in Scopus and Web of Science?
Investigational New Drugs is indexed in Web of Science, Scopus.
What is the aims and scope of Investigational New Drugs?
Investigational New Drugs is a forum for rapid dissemination of information on new anticancer agents. The journal publishes original articles dealing with anticancer drug development. It provides the fastest possible publication of new discoveries for scientists developing anticancer agents. The journal also publishes proceedings of special workshops and symposia on anticancer drug development. It is open to publishing clinical trials with negative results if they contribute to the understanding of investigational agents.
You May Also Like
See all →Data updated: 2026-05-22 · Sources: SJR, DOAJ, OpenAlex, WoS, Crossref